Skip to content
A smiling patient

Your Team

In your corner every step of the way.

As you become familiar with your United Therapeutics medication, we’re here to share our collective experience, supporting you to navigate coverage and access and providing education on your treatment.

A woman smiles texts on her phone

Get to know your United Therapeutics Cares™ team.

Patient Navigators Access & Affordability Specialists Patient Education Specialists

Patient Navigators

From enrollment on, one of our dedicated Patient Navigators will be your single point of contact. You can think of them as your guide to coverage, affordability, access, and education.

They’ll help with:

  • Providing disease and treatment education
  • Setting expectations on what’s next in your United Therapeutics treatment journey
  • Navigating insurance and confirming coverage options
  • Sharing potential options to help pay for your treatment
  • Coordinating with your Specialty Pharmacy for prescriptions and refills

Access & Affordability Specialists

Our Access & Affordability Specialists are additional team members who help navigate insurance, coverage, and financial assistance options.

They’ll help with:

  • Overseeing the benefits investigations process
  • Educating your care team on the referral requirements
  • Providing education on potential financial assistance options, like co-pay assistance

Patient Education Specialists

Our Patient Education Specialists are a valuable resource for one-on-one support, from providing education on the safe and effective use of your United Therapeutics treatment to answering questions about your disease.

They’ll help with:

  • Education on the safe and effective use of your United Therapeutics treatment
  • Sharing patient advocacy organizations in your disease space
  • Providing ongoing support and access to educational resources

United by a common goal.

United Therapeutics was founded in 1996 with a focus on treating pulmonary hypertension and related conditions. Since then, we’ve gained insights and experience with PAH and PH-ILD but also with the patient journey. This perspective is what fuels United Therapeutics Cares.

Today, our commitment hasn’t changed. We see every person as the individual they are, with unique needs we’re here to help meet.

A man looks out over a lake

Enrollment in United Therapeutics Cares™ is step one.

Get started

Already enrolled? Get in touch with your team

Expand

SELECT IMPORTANT SAFETY INFORMATION

Orenitram

  • Do not take Orenitram if you have severe liver problems.

Remodulin

  • Continuous intravenous (IV) infusions of Remodulin delivered using an external infusion pump, with a tube placed in a central vein within the chest, are associated with the risk of blood stream infections and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion delivered just beneath the skin is the preferred type of delivery.

ADCIRCA

  • ADCIRCA is a type of medication called a phosphodiesterase 5 inhibitor (PDE-5i). PDE-5’s can cause blood vessels to widen, which may result in a decrease in blood pressure. If you have heart-disease or any problems with low blood pressure, tell your healthcare provider before taking ADCIRCA, as these conditions may be affected by the action of ADCIRCA.

TYVASO and TYVASO DPI

  • Before you take TYVASO or TYVASO DPI, tell your healthcare provider about all of your medical conditions, including if you have low blood pressure or have had bleeding problems.

Please see below for Indication, additional Important Safety Information, and links to the Full Prescribing Information for Orenitram, Remodulin, ADCIRCA TYVASO, and TYVASO DPI.

SELECT IMPORTANT SAFETY INFORMATION

Orenitram

  • Do not take Orenitram if you have severe liver problems.

Remodulin

  • Continuous intravenous (IV) infusions of Remodulin delivered using an external infusion pump, with a tube placed in a central vein within the chest, are associated with the risk of blood stream infections and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion delivered just beneath the skin is the preferred type of delivery.

ADCIRCA

  • ADCIRCA is a type of medication called a phosphodiesterase 5 inhibitor (PDE-5i). PDE-5’s can cause blood vessels to widen, which may result in a decrease in blood pressure. If you have heart-disease or any problems with low blood pressure, tell your healthcare provider before taking ADCIRCA, as these conditions may be affected by the action of ADCIRCA.

TYVASO and TYVASO DPI

  • Before you take TYVASO or TYVASO DPI, tell your healthcare provider about all of your medical conditions, including if you have low blood pressure or have had bleeding problems.

Treatment options for adult patients with pulmonary arterial hypertension (PAH; WHO Group 1), which is high blood pressure in the arteries of your lungs. TYVASO and TYVASO DPI are also indicated for adult patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3).

Please see below for Indication, additional Important Safety Information, and links to the Full Prescribing Information for Orenitram, Remodulin, ADCIRCA, TYVASO, and TYVASO DPI.

What is Orenitram?

Orenitram is a prescription medicine used to treat pulmonary arterial hypertension (PAH) which is high blood pressure in the arteries of your lungs. Orenitram can help slow down the progression of your disease and improve your ability to exercise. It is not known if Orenitram is safe and effective in children.

IMPORTANT SAFETY INFORMATION FOR ORENITRAM

Who should not take Orenitram?

Do not take Orenitram if you have severe liver problems.

What should I tell my healthcare provider before taking Orenitram?

Tell your healthcare provider:

  • If you have liver problems or diverticulosis.
  • If you are pregnant, breastfeeding, and/or plan to become pregnant or breastfeed. It is not known if Orenitram will harm your unborn baby or if Orenitram passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with Orenitram.
  • About all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Orenitram and other medicines may affect each other causing side effects. Do not start any new medicine until you check with your healthcare provider. Especially tell your healthcare provider if you take another medicine that contains treprostinil, such as Remodulin® or Tyvaso®.

How should I take Orenitram?

  • Do not change your dose or suddenly stop taking Orenitram without first talking to your healthcare provider.
  • Orenitram is usually taken 3 times a day (about every 8 hours) or 2 times a day (about every 12 hours). Your healthcare provider will tell you how often you should take Orenitram. If you have side effects, your healthcare provider may tell you to change your dose or when you take Orenitram. Take Orenitram with food.
  • Swallow Orenitram tablets whole. Do not split, chew, crush, or break your Orenitram tablets. Do not take Orenitram tablets that are damaged or broken. If Orenitram tablets are not taken whole, they may release too much medicine at one time. This can lead to side effects.
  • If you miss your dose of Orenitram, take the missed dose as soon as possible with food.
  • If you miss 2 or more doses of Orenitram, call your healthcare provider to see if you need to change your dose.
  • If you take too much Orenitram, call your healthcare provider or go to the nearest hospital emergency room right away.
  • You may see the tablet shell in your stools (bowel movements). This is usually normal. The tablet shell is not digested. If you have diverticulosis, the tablet shell may get stuck in a blind pouch or diverticulum in your intestine.

What are the possible side effects of Orenitram?

Orenitram can cause serious side effects, including worsening of PAH symptoms.

  • Stopping Orenitram suddenly may cause worsening of your PAH symptoms. Do not change your dose or suddenly stop taking Orenitram without first talking to your healthcare provider.
  • The most common side effects of Orenitram include headache, diarrhea, nausea, vomiting, flushing, and pain in arms, legs, and jaw. These are not all of the possible side effects of Orenitram. Tell your healthcare provider if you have any side effect that bothers you or does not go away.
  • Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.

The risk information provided here is not comprehensive. To learn more about Orenitram, talk with your healthcare provider. Please see Full Prescribing Information and Patient Information at www.orenitram.com or call Customer Service at 1-877-UNITHER (1-877-864-8437).

OREISIconOCT19

What is Remodulin?

Remodulin is a prescription medication used to treat adults with pulmonary arterial hypertension (PAH; WHO Group 1), which is high blood pressure in the arteries of your lungs. Remodulin can reduce symptoms associated with exercise. Remodulin was studied mainly in patients with NYHA Functional Class II-IV symptoms. It is not known if Remodulin issafe and effective in children.

In people with PAH who need to switch from epoprostenol, Remodulin is approved to slow the worsening of symptoms.

IMPORTANT SAFETY INFORMATION FOR REMODULIN

Before you take Remodulin, tell your healthcare provider if you:

  • Have other medical conditions or take other medicines that may affect your use of Remodulin by increasing the risk of side effects or decreasing the drug’s effectiveness.
  • Have liver or kidney problems. Your Remodulin dose may need to be adjusted if you have liver problems.
  • Have low blood pressure or bleeding problems.
  • Are taking gemfibrozil (for high cholesterol), rifampin (for infection) or other drugs that affect liver enzymes. Your doctor may need to adjust your Remodulin dosage.
  • Are pregnant, breastfeeding, or planning to become pregnant. It is not known if Remodulin will harm your unborn baby or if Remodulin passes into your breast milk.

What are the serious side effects of Remodulin?

  • Continuous intravenous (IV) infusions of Remodulin delivered using an external infusion pump, with a tube placed in a central vein within the chest, are associated with the risk of blood stream infections and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion delivered just beneath the skin is the preferred type of delivery.
  • Worsening of PAH symptoms. Do not stop taking or greatly reduce your Remodulin dose without consulting your doctor.
  • Low blood pressure (symptomatic hypotension). If you have low blood pressure or are taking drugs that lower your blood pressure, the risk of low blood pressure is increased.
  • Bleeding problems. Remodulin may increase the risk of bleeding in people who take blood thinners (anticoagulants).

What are the possible side effects of Remodulin?

  • In clinical studies of SC infusion of Remodulin, most people experienced infusion site pain and infusion site reaction (redness, swelling, and rash). These symptoms were sometimes severe and sometimes required treatment with narcotics or discontinuation of Remodulin.
  • IV infusion of Remodulin delivered through an external pump has been associated with the risk of blood stream infections, arm swelling, tingling sensations, bruising, and pain.
  • The most common side effects seen with either SC or IV Remodulin were headache, diarrhea, nausea, rash, jaw pain, widening of the blood vessels (vasodilatation), and swelling from fluid retention (edema). These are not all the possible side effects of Remodulin. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.

The risk information provided here is not comprehensive. To learn more about Remodulin, talk with your healthcare provider. Please see Full Prescribing Information at www.remodulin.com or call Customer Service at 1-877-UNITHER (1-877-864-8437).

REMISIconMAY2021

Important Safety Considerations for ADCIRCA® (tadalafil)

  • You should discuss all of your medical conditions and all medications with your healthcare provider before starting ADCIRCA
  • Do not take ADCIRCA if you take any medications that contain nitrates (often used for chest pain) or guanylate cyclase stimulators, as the combination could cause a sudden, unsafe drop in blood pressure
  • Do not take ADCIRCA if you are allergic to tadalafil or any other ingredient in ADCIRCA
  • ADCIRCA is a type of medication called a phosphodiesterase 5 inhibitor (PDE-5i) that can cause blood vessels to widen, which may result in a decrease in blood pressure. If you have heart-disease or any problems with low blood pressure, tell your healthcare provider before taking ADCIRCA, as these conditions may be affected by the action of ADCIRCA
  • Talk with your healthcare provider if you are pregnant or planning to become pregnant or if you are breastfeeding or plan to breast feed.
  • If you have ever had blockage in the veins of your lungs, known as pulmonary veno-occlusive disease (PVOD), ADCIRCA is not recommended for you
  • Taking ADCIRCA with alcohol, or blood pressure medications, such as alpha-blockers, may lower blood pressure and cause hypotension (light-headedness or fainting)
  • Do not take ADCIRCA if you are taking rifampin (an antibiotic for certain bacterial infections), or antifungal medications, such as ketoconazole and itraconazole. If you require treatment with both ADCIRCA and ritonavir (Norvir®) at the same time, your dose of ADCIRCA will need to be adjusted. Inform your healthcare provider if you have kidney or liver problems before taking ADCIRCA
  • ADCIRCA contains the same ingredient (tadalafil) as Cialis®, which is used to treat erectile dysfunction (ED, impotence) and the signs and symptoms of benign prostatic hyperplasia (BPH, enlarged prostate). If you are taking ADCIRCA, do not take Cialis or other PDE-5is
  • In rare cases, patients reported side effects such as decreased eyesight or loss of vision in one or both eyes (NAION), or sudden decrease or loss of hearing, sometimes with ringing in the ears and dizziness. If you experience any of these side effects after taking ADCIRCA, seek medical attention right away
  • In rare cases, men taking PDE-5is (including tadalafil) for erectile dysfunction reported side effects such as an erection lasting more than four hours. If you experience a prolonged erection, seek medical attention right away
  • The most common side effects of ADCIRCA are headache, muscle pain, getting red or hot in the face (flushing), nausea, pain in the arms, legs or back, upset stomach, stuffy or congested nose

ADC.ISI.CON.SEP2020

For more information about ADCIRCA, please see the Full Prescribing Information and
Patient Information or call 1-800-545-5979.

Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.

What are TYVASO and TYVASO DPI?

TYVASO (treprostinil) Inhalation Solution and TYVASO DPI (treprostinil) Inhalation Powder are prescription medicines used in adults to treat:

  • Pulmonary arterial hypertension (PAH; WHO Group 1), which is high blood pressure in the arteries of your lungs. TYVASO or TYVASO DPI can improve the ability to exercise. Your ability to exercise decreases 4 hours after taking TYVASO or TYVASO DPI. It is not known if TYVASO or TYVASO DPI is safe and effective in children under 18 years of age.
  • Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), which is high blood pressure in the lungs due to inflammation and sometimes scarring in the lungs. TYVASO or TYVASO DPI can improve the ability to exercise.

IMPORTANT SAFETY INFORMATION FOR TYVASO and TYVASO DPI

Before you take TYVASO or TYVASO DPI, tell your healthcare provider about all of your medical conditions, including if you:

  • Have low blood pressure
  • Have or have had bleeding problems
  • Have asthma or chronic obstructive pulmonary disease (COPD)
  • Are pregnant or plan to become pregnant. It is not known if either product will harm your unborn baby.
  • Are breastfeeding or plan to breastfeed. It is not known if either product passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Either product and other medicines may affect each other.

Especially tell your healthcare provider if you take:

  • Medicines used to treat high blood pressure or heart disease
  • Medicines that decrease blood clotting (anticoagulants)
  • Water pills (diuretics)
  • Gemfibrozil (Lopid®) or rifampin (Rimactane®, Rifadin®, Rifamate®, Rifater®)

What are the possible side effects of TYVASO or TYVASO DPI?

Both products can cause serious side effects, including:

  • Low blood pressure (symptomatic hypotension). If you have low blood pressure, either product may lower your blood pressure more.
  • Bleeding problems. Either product may increase the risk of bleeding, especially in people who take blood thinners (anticoagulants).

The most common side effects of both products are cough, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), fainting or loss of consciousness, dizziness, diarrhea, and shortness of breath. Like other inhaled prostaglandins, you may have trouble breathing after taking TYVASO or TYVASO DPI because it may cause the muscles around your airway to tighten (bronchospasm). These are not all the possible side effects. Call your doctor for medical advice about side effects or if you have trouble breathing.

You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.

The risk information provided here is not comprehensive. To learn more about TYVASO or TYVASO DPI, talk with your healthcare provider. Please see Full Prescribing Information for TYVASO or TYVASO DPI, Instructions for Use manuals for TD-100 and TD-300 TYVASO® Inhalation System and TYVASO DPI™ Inhalation Powder, and additional information at www.TYVASO.com or call 1-877-UNITHER (1-877-864-8437).

TYVISIconMAY2022